Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Kolland, M; Sartori, S; Klivinyi, C; Schörghuber, M; Pannold, J; Knez, I; Kirsch, AH; Schreiber, N.
Preoperative SGLT2i therapy and acute kidney injury in patients undergoing emergency and urgent coronary artery bypass grafting - A causal inference framework.
J Clin Anesth. 2026; 109:112103 Doi: 10.1016/j.jclinane.2025.112103
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Kolland Michael
Schreiber Nikolaus
Co-Autor*innen der Med Uni Graz
Kirsch Alexander
Klivinyi Christoph
Knez Igor
Pannold Jakob
Sartori Selina
Schörghuber Michael
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND: Acute kidney injury (AKI) is a common complication after coronary artery bypass grafting (CABG), associated with adverse short- and long-term outcomes. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce occurrence of AKI in several populations, yet their perioperative effects in patients undergoing CABG are unknown. METHODS: We conducted a retrospective study at the Department of Cardiac Surgery, Medical University of Graz (2020-2024) to evaluate the impact of preoperative SGLT2i use on cardiac surgery-associated AKI in adults undergoing urgent or emergent isolated coronary artery bypass grafting in patients with an indication for SGLT2i therapy (type 2 diabetes mellitus, heart failure with reduced ejection fraction, or chronic kidney disease). Patients with preoperative dialysis, sepsis, reoperation, mechanical circulatory support or missing laboratory data were excluded. Exposure was defined as SGLT2i use within two weeks before surgery, and the primary outcome was cardiac surgery-associated AKI (CSA-AKI) according to KDIGO criteria. Secondary outcomes included kidney replacement therapy, ICU length of stay, 30-day mortality and postoperative diabetic ketoacidosis. Causal effects were estimated using entropy balancing. Results were reported as weighted risk differences, risk ratios, and adjusted mean differences, with time-to-event outcomes analyzed via weighted Cox models and Kaplan-Meier estimates. RESULTS: Among 484 patients, 135 were on SGLT2i. CSA-AKI occurred in 23.0 % of SGLT2i users vs. 28.1 % of non-users (risk ratio of 0.63 [95 % CI 0.44-0.91; p = 0.014]). The association was pronounced in patients with heart failure with reduced ejection fraction and those with high EuroSCORE II. No differences were observed in other secondary endpoints and no cases of postoperative diabetic ketoacidosis occurred. CONCLUSION: Preoperative SGLT2i use was associated with a significantly lower risk of CSA-AKI in patients undergoing urgent or emergent CABG. These findings need to be confirmed in prospective multicenter trials but underline the favorable safety profile of this medication.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Acute Kidney Injury - epidemiology, etiology, prevention & control
Male - administration & dosage
Retrospective Studies - administration & dosage
Female - administration & dosage
Aged - administration & dosage
Middle Aged - administration & dosage
Coronary Artery Bypass - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use, administration & dosage
Postoperative Complications - epidemiology, prevention & control, etiology
Diabetes Mellitus, Type 2 - drug therapy, complications
Preoperative Care - methods
Length of Stay - statistics & numerical data
Heart Failure - complications
Risk Factors - administration & dosage
Diabetic Ketoacidosis - epidemiology
Renal Replacement Therapy - statistics & numerical data

Find related publications in this database (Keywords)
Acute kidney injury
Coronary artery bypass grafting
Sodium-glucose cotransporter-2 inhibitors
Causal inference
Perioperative outcomes
© Med Uni Graz • Impressum